{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T13:34:24Z","timestamp":1769002464255,"version":"3.49.0"},"reference-count":41,"publisher":"Academy of Managed Care Pharmacy","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMCP"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.18553\/jmcp.2022.22208","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T16:03:56Z","timestamp":1672329836000},"page":"69-79","source":"Crossref","is-referenced-by-count":3,"title":["Matching-adjusted indirect comparison of phase 3 clinical trial outcomes of OC-01 (varenicline solution) nasal spray and lifitegrast 5% ophthalmic solution for the treatment of dry eye disease"],"prefix":"10.18553","volume":"29","author":[{"given":"Darrell E","family":"White","sequence":"first","affiliation":[{"name":"Sky Vison Center, Westlake, OH."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura H","family":"Hendrix","sequence":"additional","affiliation":[{"name":"Oyster Point Pharma, Inc., Princeton, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucille","family":"Sun","sequence":"additional","affiliation":[{"name":"COEUS Consulting Group, Philadelphia, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Tam","sequence":"additional","affiliation":[{"name":"COEUS Consulting Group, Philadelphia, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian","family":"Macsai","sequence":"additional","affiliation":[{"name":"Oyster Point Pharma, Inc., Princeton, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea A","family":"Gibson","sequence":"additional","affiliation":[{"name":"Oyster Point Pharma, Inc., Princeton, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7818","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21239271"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0b013e318181a947"},{"issue":"2","key":"R3","first-page":"1611","volume":"50","author":"Guo OD LW","year":"2020","journal-title":"Turk J Med Sci"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-039209"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2020.03.044"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2015.11.002"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1080\/08164622.2021.1887580"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2021-000709"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e3181f7f363"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.006"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.10.023"},{"key":"R12","unstructured":"Center for Drug Evaluation and Research. Drup approval letters for Restasis. US Food and Drug Administration. Accessed October 28, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/21-023_Restasis_Approv.PDF"},{"key":"R13","unstructured":"Center for Drug Evaluation and Research. Drug approval for CEQUA. US Food and Drug Administration. Accessed October 28, 2021. https:\/\/www.access-data.fda.gov\/drugsatfda_docs\/appletter\/2018\/210913Orig1s000ltr.pdf"},{"key":"R14","unstructured":"Center for Drug Evaluation and Research. Drug approval for Xiidra. US Food and Drug Administration. Accessed October 28, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208073Orig1s000StatR.pdf"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S279051"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.18433\/jpps29895"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2021.07.020"},{"key":"R18","unstructured":"Center for Drug Evaluation and Research. Drug approval for Chantix. US Food and Drug Administration. Accessed October 28, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2006\/021928s000ltr.pdf"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462319000333"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X17725740"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211049639"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.259"},{"key":"R25","first-page":"115","author":"Mt-Isa S","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01298-x"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000002941"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.09.015"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.08.001"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S152841"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171279"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1198\/073500102288618630"},{"key":"R34","unstructured":"R: A language and environment for statistical computing. R Foundation for Statistical Computing; 2020."},{"key":"R36","unstructured":"Center for Drug Evaluation and Research. Dry eye: Developing drugs for treatment guidance for industry. US Food and Drug Administration. December 2020. Accessed April 26, 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/dry-eye-developing-drugs-treatment-guidance-industry"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2021.3943"},{"key":"R38","first-page":"795","volume":"10","author":"Friedman NJ","year":"2016","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"R39","first-page":"2692","volume":"58","author":"Orrick B","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-21362"},{"key":"R41","doi-asserted-by":"publisher","DOI":"10.2165\/11538370-000000000-00000"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.01.015"},{"key":"R43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.10.011"},{"key":"R44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.11.004"}],"container-title":["Journal of Managed Care & Specialty Pharmacy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T22:26:13Z","timestamp":1673648773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmcp.org\/doi\/10.18553\/jmcp.2022.22208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.18553\/jmcp.2022.22208"],"URL":"https:\/\/doi.org\/10.18553\/jmcp.2022.22208","relation":{},"ISSN":["2376-0540","2376-1032"],"issn-type":[{"value":"2376-0540","type":"print"},{"value":"2376-1032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}